$23.61
13.42% day before yesterday
Nasdaq, Jan 02, 10:17 pm CET
ISIN
US34962G1094
Symbol
FBRX

Forte Biosciences Inc Stock price

$23.61
+4.52 23.68% 1M
+9.77 70.59% 6M
-3.66 13.42% YTD
-1.66 6.57% 1Y
-1.39 5.56% 3Y
-857.89 97.32% 5Y
-4,645.14 99.49% 10Y
-4,645.14 99.49% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-3.66 13.42%
ISIN
US34962G1094
Symbol
FBRX
Industry

Key metrics

Basic
Market capitalization
$295.8m
Enterprise Value
$202.4m
Net debt
positive
Cash
$93.4m
Shares outstanding
12.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
85.3%
Return on Equity
-66.7%
ROCE
-63.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-53.4m | -
EBIT
$-53.4m | $-66.6m
Net Income
$-51.7m | $-54.9m
Free Cash Flow
$-44.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-49.2% | -
EBIT
-49.2% | -80.1%
Net Income
-49.2% | -56.7%
Free Cash Flow
-47.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.9
FCF per Share
$-3.5
Short interest
4.5%
Employees
14
Rev per Employee
$0.0
Show more

Is Forte Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Forte Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Forte Biosciences Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Forte Biosciences Inc forecast:

Buy
92%
Hold
8%

Financial data from Forte Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
27% 27%
-
- Research and Development Expense 42 42
114% 114%
-
-53 -53
49% 49%
-
- Depreciation and Amortization 0.05 0.05
25% 25%
-
EBIT (Operating Income) EBIT -53 -53
49% 49%
-
Net Profit -52 -52
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Forte Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Forte Biosciences Inc Stock News

Neutral
Business Wire
12 days ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Ma...
Neutral
Business Wire
about one month ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Ma...
Neutral
Business Wire
about 2 months ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025 financial results and provided a business update. “We continue to make excellent progress with FB102,” said Forte Biosciences CEO Paul Wagner, PhD. “The US IND is now open an...
More Forte Biosciences Inc News

Company Profile

Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.

Head office United States
CEO Paul Wagner
Employees 14
Founded 2017
Website www.fortebiorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today